Startup profile · funding coverage
Curie.Bio
Biotech accelerator and VC pairing seed capital with drug-discovery co-pilot services for pre–Series A therapeutics.
Stage
See coverage
Status
private
Coverage
full
Why Curie.Bio is interesting
Curie.Bio is itself a fund/platform — a16z and ARCH co-back the vehicle that writes $5–15M seed checks and runs vendor-heavy R&D ops for founders.
Key facts
- Launch (2022): $520M across seed + services vehicles; backers include ARCH Venture Partners, GV, and a16z (Fierce Biotech)
- Seed fund (Jan 2025): +$340M to invest in 15–25 therapeutics startups/year (STAT)
Investors in our directory
Funds linked from Curie.Bio's profile — open a fund page for stage focus and related deal articles.
Industries
Biotech & Life Sciences Healthtech
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
FAQs about Curie.Bio
Funding context and why this company shows up in venture coverage.
Curie.Bio is a biotech venture firm and accelerator — it writes $5–15M seed checks in pre–Series A therapeutics companies and provides embedded drug-discovery services (CRO management, lab operations, regulatory support) to portfolio founders.
ARCH Venture Partners (see /fund/arch-venture-partners) and Andreessen Horowitz (see /fund/andreessen-horowitz) are among the backers of Curie.Bio's fund vehicles. GV also participated in the launch.
Curie.Bio is a venture fund/platform, not a traditional startup. It launched in 2022 with $520M and added $340M to its seed fund in January 2025.
Early-stage biotech founders often lack operational infrastructure. Curie.Bio tests whether combining capital with hands-on R&D services can accelerate therapeutics from seed to Series A — a model distinct from traditional VC.
Curie.Bio is a private venture firm, not a public company. It invests in portfolio startups rather than operating as a standalone product company.
Last updated: 2026-07-24